Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-04-21 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
2023年年度财务报告
Annual Report Classification · 95% confidence The document is titled as the 2023 annual financial settlement report of Enwei Pharmaceutical Co., Ltd. It includes detailed financial statements such as income, net profit, cash flow, assets, liabilities, and financial ratios for the year 2023 compared to 2022. It also mentions the audit report issued by an accounting firm with an audit opinion on the financial statements. The content is comprehensive and contains actual financial data and analysis for the full fiscal year 2023. The document length is 4377 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K) rather than a report publication announcement or regulatory filing. Hence, the classification is 10-K with high confidence. FY 2023
2024-04-21 Chinese
2023年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2023 of 恩威医药股份有限公司. It contains detailed audit opinions, basis for audit, key audit matters, responsibilities of management and auditors, and extensive financial statements including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The content is comprehensive and includes auditor's detailed commentary and financial data, consistent with a standalone audit report rather than a full annual report or other filing types. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2023
2024-04-21 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2024年度预计日常关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion from a sponsoring institution (中信证券股份有限公司) regarding the expected related party transactions for the year 2024 of 恩威医药股份有限公司. It includes descriptions of the related party, transaction amounts, pricing principles, and compliance with regulatory rules. The document is not a full financial report but rather a verification or audit opinion on expected related party transactions, which aligns with an audit or review type of filing. The document length is 3488 characters, which is relatively short but contains substantive content about the audit of related party transactions rather than just an announcement. It is not an annual report, interim report, or earnings release. It is not a regulatory filing or announcement. Therefore, the best fit is Audit Report / Information (AR), as it is a standalone audit opinion on related party transactions for the upcoming year. FY 2024
2024-04-21 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "恩威医药股份有限公司 2023 年年度报告全文" which translates to "Enwei Pharmaceutical Co., Ltd. 2023 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management analysis, and comprehensive disclosures for the fiscal year 2023. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-21 Chinese
关于续聘2024年度财务审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of the company's financial audit firm for the year 2024. It details the audit firm's qualifications, independence, audit fees, and the approval process involving the audit committee, board of directors, and supervisory board. There is no actual audit report or financial statements included, nor is there a detailed audit opinion or results. The document is a formal announcement about the audit firm appointment, not the audit report itself. The document length is relatively short (2713 characters), and it serves as a notice to shareholders and the public about the audit firm reappointment. Therefore, it fits best under 'Audit Report / Information (AR)' as it relates to audit information but is not a full annual report or audit report document. However, since it is an announcement about the audit firm appointment rather than the audit report itself, and given the definitions, it is more appropriate to classify this as a Regulatory Filing (RNS) because it is a regulatory announcement about audit firm reappointment without substantive audit results or financial data.
2024-04-21 Chinese
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2023 annual financial settlement report of Enwei Pharmaceutical Co., Ltd. It includes detailed financial statements such as income, net profit, cash flow, assets, liabilities, and financial ratios for the full year 2023. It also mentions the audit report issued by an accounting firm with an audit opinion on the financial statements. The content is comprehensive and covers the full fiscal year financial performance and position, which is characteristic of an Annual Report (10-K). The document length is 4377 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, it should be classified as an Annual Report (10-K). FY 2023
2024-04-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.